Health
Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease – nejm.org
Original Article from The New England Journal of Medicine — Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
From the DanaFarber/Boston Childrens Cancer and Blood Disorders Center, Harvard Medical School (E.B.E., L.E.L., A.B., C.B., M.F.C., B.M., K.B., S.-Y.P., W.B.L., C.D., M.M.H., D.A.W.), the Harvard Stem Cell Institute, Harvard Medical School (A.B., C.B.), the Gene Therapy Program, DanaFarber/Boston Childrens Cancer and Blood Disorders Center (A.B., M.F.C., B.M., E.M., A.F., S.-Y.P., C.D., D.A.W.), the Division of Hematology, Brigham and Womens Hospital, Harvard Medical School (M. Achebe), the Connell…
-
Noosa News18 hours agoWhere, when and why? Everything you need to know about Sunday’s pro-Palestine protest march in Brisbane
-
General23 hours agoNew Spirit of Tasmania ferry arrives in Hobart, but will not be operating for more than a year
-
Noosa News23 hours agoScientists move precious ReefHQ coral ahead of Great Barrier Reef Aquarium build
-
General24 hours agoWA government is ‘spinning’ the results of community survey into Burswood Park racetrack and community hub, locals say